Chronic Liver Disease
Conditions
Keywords
ARFI imaging, normal values, chronic liver disease, liver donors, kidney donors
Brief summary
This is a prospective cohort Study for evaluation of liver fibrosis staging with acoustic radiation force impulse elastography in patients with chronic liver disease and healthy liver/kidney donors.
Detailed description
A recent new method for liver fibrosis assessment based on similar technology to transient elastography is acoustic radiation force impulse (ARFI) imaging. ARFI has the advantages which can be conducted in parallel ways of measuring points in the patients with chronic liver disease when they underwent routine ultrasound examination. Thus, the aim of this study was to identify the normal range of ARFI velocity and assess the best cut-off value by recruiting healthy living liver and kidney donors.
Interventions
Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
Sponsors
Severance Hospital
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Age \> 20 years * chronic liver disease (hepatitis B, hepatitis C, liver cirrhosis) patients who are planned to liver biopsy * Healthy liver and kidney donors * The patients who is willing and able to provide written informed consent to participate in this study
Exclusion criteria
* Decompensated liver cirrhosis * Patients with liver congestion due to heart dysfunction * Patients who previously take antiviral agent and antifibrotic agent * Healthy liver and kidney donors with any laboratory abnormalities regarding liver condition (Platelet count \< 150 x 103/ul, Fasting glucose \> 110 mg/dl, AST \> 40 IU/L, ALT\> 40 IU/L, Albumin \< 3.3 g/dl, Total bilirubin \> 1.2 mg/dl, GGT\> 54 IU/L, ALP \> 115 IU/L , Ferritin \> 322 ng/ml) * A history of any other medical disease or condition that would make the patients unsuitable for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluation of ARFI velocity in healthy donors and patients with chronic liver disease | 2 years | Measurement of ARFI velocity is non-invsive ultrasonographic technique. It is performed with a abdominal convex probe which is same probe as conventional ultrasonography. Short-duration acoustic radiation forces result in shear-wave propagation away from the region of excitation and are tracked using ultrasonic correlation-based methods. This results are called ARFI velocity which is expressed as meters per second |
Countries
South Korea
Outcome results
None listed